Beigene Ltd (BGNE.OQ)
126.02USD
25 Mar 2019
$1.56 (+1.25%)
$124.46
$125.00
$126.97
$122.00
74,378
189,090
$220.09
$105.19
Latest Key Developments (Source: Significant Developments)
Beigene Receives U.S. FDA Breakthrough Therapy Designation For Zanubrutinib
Jan 15 (Reuters) - Beigene Ltd <6160.HK>::RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZANUBRUTINIB IN MANTLE CELL LYMPHOMA. Full Article
Beigene Receives FDA Breakthrough Therapy Designation For Zanubrutinib In Mantle Cell Lymphoma
Jan 14 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZANUBRUTINIB IN MANTLE CELL LYMPHOMA. Full Article
Beigene Presents Preliminary Clinical Trial Data In Patients With Solid Tumors
Oct 22 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE PRESENTS PRELIMINARY CLINICAL DATA ON PARP INHIBITOR PAMIPARIB IN COMBINATION WITH LOW-DOSE TEMOZOLOMIDE IN PATIENTS WITH SOLID TUMORS AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) 2018 CONGRESS.BEIGENE LTD - TWO PATIENTS EXPERIENCED AES RESULTING IN DISCONTINUATION OF PAMIPARIB AND TMZ, ONE CONSIDERED RELATED TO STUDY TREATMENT.BEIGENE LTD - PRELIMINARY RESULTS, SAFETY AND TOLERABILITY PROFILE, SUPPORT CONTINUED DEVELOPMENT OF THE COMBINATION. Full Article
MEI Pharma And Beigene Announce Clinical Collaboration
Oct 11 (Reuters) - Beigene Ltd <6160.HK>::MEI PHARMA AND BEIGENE ANNOUNCE CLINICAL COLLABORATION TO EVALUATE ME-401 IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES.MEI PHARMA INC - STUDY COSTS WILL BE SHARED EQUALLY BY PARTIES, AND MEI WILL SUPPLY ME-401 AND BEIGENE WILL SUPPLY ZANUBRUTINIB.MEI PHARMA INC - UNDER TERMS OF CLINICAL COLLABORATION AGREEMENT, MEI WILL AMEND ITS ONGOING PHASE 1B TRIAL.MEI PHARMA INC - WILL RETAIN FULL COMMERCIAL RIGHTS FOR ME-401 & BEIGENE WILL RETAIN FULL COMMERCIAL RIGHTS FOR ZANUBRUTINIB.MEI PHARMA - AMENDMENT OF ONGOING PHASE 1B TRIAL TO INCLUDE EVALUATION OF ME-401 IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES. Full Article
Beigene Announces Preliminary Results From The Phase 1 Clinical Trial Of Zanubrutinib
Sept 21 (Reuters) - Beigene Ltd 6160.HK::BEIGENE ANNOUNCES PRELIMINARY RESULTS FROM THE PHASE 1 CLINICAL TRIAL OF ZANUBRUTINIB IN CHINESE PATIENTS WITH B-CELL LYMPHOMA AT ANNUAL MEETING OF THE CHINESE SOCIETY OF CLINICAL ONCOLOGY.BEIGENE LTD - NEW DRUG APPLICATION FILING FOR ZANUBRUTINIB IN CHINA IS CURRENTLY UNDER REVIEW BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA.BEIGENE -PRELIMINARY FINDINGS SUGGESTED THERE WAS NO SIGNIFICANT DIFFERENCE IN PHARMACOKINETIC PROFILE OF ZANUBRUTINIB BETWEEN CHINESE AND NON-CHINESE PATIENTS.BEIGENE LTD - NO DEATHS RELATED TO ADVERSE EVENTS WERE OBSERVED IN THE TRIAL. Full Article
Beigene And Springworks Therapeutics Collaborate To Evaluate Targeted Combination Therapy In Advanced Solid Tumors
Sept 6 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE AND SPRINGWORKS THERAPEUTICS ENTER INTO GLOBAL CLINICAL COLLABORATION TO EVALUATE TARGETED COMBINATION THERAPY IN ADVANCED SOLID TUMORS.BEIGENE LTD - BEIGENE'S RAF DIMER INHIBITOR LIFIRAFENIB (BGB-283) AND SPRINGWORKS THERAPEUTICS' MEK INHIBITOR PD-0325901 TO BE STUDIED IN COMBINATION.BEIGENE LTD - COMBINATION APPROACH WILL TARGET RAS MUTATIONS COMMON IN MANY CANCERS IN COLLABORATION.BEIGENE LTD - PHASE 1B CLINICAL STUDY EXPECTED TO COMMENCE IN Q1 OF 2019.BEIGENE LTD - PHASE 1B CLINICAL STUDY EXPECTED TO COMMENCE IN Q1 OF 2019.BEIGENE LTD - BEIGENE WILL BE RESPONSIBLE FOR ADMINISTERING PHASE 1B CLINICAL TRIAL. Full Article
Beigene Announces Acceptance Of NDA For Tislelizumab In Hodgkin’s Lymphoma In China
Aug 31 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE ANNOUNCES ACCEPTANCE OF NEW DRUG APPLICATION FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB IN HODGKIN’S LYMPHOMA IN CHINA.BEIGENE - NMPA ACCEPTED NDA FOR TISLELIZUMAB AS POTENTIAL TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA. Full Article
Shares Of Beigene Set To Open On Hong Kong Debut Flat At HK$108.00
Aug 8 (Reuters) - Beigene Ltd <6160.HK>::SET TO OPEN ON HONG KONG DEBUT AT HK$108.00 VERSUS HK$108.00 ISSUE PRICE. Full Article
Beigene Anticipates That The Public Offering Price Will Be Between Hk$94.40 And Hk$111.60 Per Share, Or Between About $12.03 And $14.22 Per
July 27 (Reuters) - Beigene Ltd
Beigene Announces Proposed Hong Kong Initial Public Offering And Global Offering
July 27 (Reuters) - Beigene Ltd
UPDATE 2-Shanghai Junshi Biosciences soars on HK debut after $394 mln IPO
* Junshi Biosciences taking advantage of new listing rules in HK
Earnings vs. 
Estimates